My job as a biologist in the lab used to consist of moving liquids back and forth by hand. At Zymergen, I’m training robots to automate the worst parts of that job, and I’m here to tell you why you should look forward to fully automated luxury science.
By merging enEvolv’s powerful platform technology with our existing genome engineering, automation and machine learning capabilities, we will dramatically improve our ability to discover, design and commercialize breakthrough biologically-manufactured products.
The World Economic Forum and McKinsey recently published a whitepaper in which they recognize Zymergen as a “lighthouse company”, helping drive what they characterize as the Fourth Industrial Revolution (they also presented us with a lighthouse award, which a number of my colleagues shared from Davos).
At Zymergen, we use biology to create never-before imagined materials. As we continue to scale and build our growing pipeline of next generation products, we’re proud to announce that we’ve appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to Zymergen’s Board of Directors. Jay will serve as Lead Independent Director.
No one would sell us a high-throughput lab automation system that could be reconfigured in minutes and would scale to fill a factory. So we built one.